EP0683675A4 - Anticorps monoclonaux humains contre le cytomegalovirus. - Google Patents

Anticorps monoclonaux humains contre le cytomegalovirus.

Info

Publication number
EP0683675A4
EP0683675A4 EP94908670A EP94908670A EP0683675A4 EP 0683675 A4 EP0683675 A4 EP 0683675A4 EP 94908670 A EP94908670 A EP 94908670A EP 94908670 A EP94908670 A EP 94908670A EP 0683675 A4 EP0683675 A4 EP 0683675A4
Authority
EP
European Patent Office
Prior art keywords
cytomegalovirus
monoclonal antibodies
human monoclonal
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94908670A
Other languages
German (de)
English (en)
Other versions
EP0683675A1 (fr
Inventor
Lars G Ostberg
Paul Nadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharmaceuticals Corp
Original Assignee
Sandoz Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Pharmaceuticals Corp filed Critical Sandoz Pharmaceuticals Corp
Publication of EP0683675A1 publication Critical patent/EP0683675A1/fr
Publication of EP0683675A4 publication Critical patent/EP0683675A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP94908670A 1993-01-28 1994-01-28 Anticorps monoclonaux humains contre le cytomegalovirus. Withdrawn EP0683675A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1022893A 1993-01-28 1993-01-28
US7380893A 1993-06-09 1993-06-09
US73808 1993-06-09
PCT/US1994/001068 WO1994016730A1 (fr) 1993-01-28 1994-01-28 Anticorps monoclonaux humains contre le cytomegalovirus
US10228 1996-01-19

Publications (2)

Publication Number Publication Date
EP0683675A1 EP0683675A1 (fr) 1995-11-29
EP0683675A4 true EP0683675A4 (fr) 1997-05-21

Family

ID=26680936

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94908670A Withdrawn EP0683675A4 (fr) 1993-01-28 1994-01-28 Anticorps monoclonaux humains contre le cytomegalovirus.

Country Status (5)

Country Link
EP (1) EP0683675A4 (fr)
JP (1) JPH08506325A (fr)
AU (1) AU695584B2 (fr)
CA (1) CA2153790A1 (fr)
WO (1) WO1994016730A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
AU2001259379B2 (en) * 2000-05-03 2006-08-03 Medimmune, Llc Combination therapy of respiratory diseases using antibodies
WO2007094423A1 (fr) * 2006-02-15 2007-08-23 Evec Incorporated Anticorps monoclonal humain capable de se lier au cytomegalovirus humain et domaine de liaison antigene de l'anticorps
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
EP3766517B1 (fr) 2008-06-20 2022-11-02 Duke University Compositions, procédés et kits permettant de provoquer une réponse immunitaire
PE20141432A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
KR101390015B1 (ko) 2009-04-01 2014-04-29 에베크 인코포레이티드 인간 사이토메갈로바이러스 ｇＢ 당단백질의 ＡＤ1 영역에 존재하는 특정한 불연속 에피토프에 결합하는 모노클로날 항체 및 그의 항원 결합성 단편
EA201390467A1 (ru) * 2010-09-29 2013-11-29 Дженентек, Инк. Композиции антител и способы применения
CA3086098A1 (fr) 2017-12-19 2019-06-27 F-Star Beta Limited Sequences de liaison specifiques a pd-l1 inserees dans un domaine ch3
MX2021000398A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a pd-l1 y cd137.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUMMER: "CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION: CLINICAL MANIFESTATIONS AND STRATEGIES FOR PREVENTION", REVIEWS OF INFECTIOUS DISEASES, vol. 12, no. S7, 1990, pages S767 - S775, XP000647578 *
NOKTA ET AL: "HUMAN MONOCLONAL ANTI CYTOMEGALOVIRUS (CMV) ANTIBODY (MSL-109): ENHANCEMENT OF IN VITRO FOSCARNET INDUCED INHIBITION OF CMV REPLICATION", ANTIVIRAL RESEARCH, vol. 17, no. S1, 1992, pages 97, XP002027786 *
See also references of WO9416730A1 *
STRATTA ET AL: "CYTOMEGALOVIRUS INFECTION AND DISEASE AFTER LIVER TRANSPLANTATION. AN OVERVIEW", DIGESTIVE DISEASES AND SCIENCES, vol. 37, 1992, pages 673 - 688, XP000647567 *

Also Published As

Publication number Publication date
CA2153790A1 (fr) 1994-08-04
JPH08506325A (ja) 1996-07-09
EP0683675A1 (fr) 1995-11-29
AU695584B2 (en) 1998-08-20
AU6167794A (en) 1994-08-15
WO1994016730A1 (fr) 1994-08-04

Similar Documents

Publication Publication Date Title
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
ZA949341B (en) Humanized antibodies and uses thereof
EP0627932A4 (fr) Nouvelle structure d'anticorps.
IL130864A0 (en) Monoclonal antibodies to human cd6
AU4618193A (en) Humanized antibodies
GB9412166D0 (en) Retargetting antibodies
EP0578515A3 (fr) Anticorps monoclonaux humanisés.
EP0580859A4 (en) Anti-eda monoclonal antibody
EP0683675A4 (fr) Anticorps monoclonaux humains contre le cytomegalovirus.
IL90017A0 (en) Monoclonal antibodies
AU6155896A (en) Humanized antibodies to e-selectin
ZA898777B (en) Monoclonal antibodies
EP0506523A3 (en) Monoclonal antibodies
EP0977590A4 (fr) Anticorps monoclonaux humains
IL92232A0 (en) Anti-fucosylceramide monoclonal antibody
AU6777594A (en) Human monoclonal antibodies to human cytomegalovirus, and methods therefor
ZA89258B (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
GB8927389D0 (en) Monoclonal antibodies
EP0654532A4 (fr) Anticorps monoclonal antimucoglycoproteine.
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0336441A3 (en) Anti-cpbii monoclonal antibody
EP0668923A4 (fr) Anticorps monoclonal.
GB9320508D0 (en) Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970407

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020409